Limited pharmacokinetic data for cefoperazone are available from the parturient. Because cefoperazone has a dual excretory patterni, primarily via the biliary system and secondarily via the kidney, pregnancy-induced physiologic alterations can influence its deposition and cleltrance. Twelve term parturients receiving cefoperazone prophylaxis after cesarean section were selected for study. After 2 g of cefoperazone was administered for 1 h intravenously, serial blood samples were assayed by high-pressure liquid chromatography, Plasma protein binding of cefoperazone was studied in vitro. The mean peak cefoperazone concentration ± standard deviation was 169.9 ± 60.4 ,ug/ml. The mean half4life was 152 min. Total serum clearance was 80.8 ± 30.8 ml/mhin. The steady-state volume of distribution was 14.2 ± 6.0 liters. All subjects had detectable trough levels at the end of the dosage interval, with a mean value of 6.5 + 5.2 ,ug/ml. Protein binding of cefoperazone for parturients was 74.3 ± 10.9%, comnpared with 87.7 ± 3.2% in nonpregnaimt controls (P < 0.05). These data suggest that cefoperazone deposition can be greatly influenced by pregnancy. However, unlike several other new anti-icrobial agents whose excretions are mainly renal, the cefoperazone half-lire and thus trough concentration for the parturient more closely resemble that for the nonpregnant subject.
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Cefoperazone has been shown to be efficacious in a variety of clinical settings by virtue of its broad range of antibacterial activity. In particular, because the obstetric patient who develops post-cesarean-section sepsis is most often infected by a polymicrobial insult, broad-spectrum antimicrobial agents have justified the single-drug approach of the clihician to therapy (4, 12) . However, recognition of physiologic alterations which normally occur in the parturient is important, because these changes may directly influence the pharmacokinetic behavior of a given drug and therefore its clinical utility (10) . In this regard, cefoperazone has been shown to exhibit an excretion pattern primarily via the biliary system and secondarily through the kidneys (3 The steady-state volume of distribution (Vs5) was calculated from the following relationship: V,5 = dose (AUMC)/(AUC)2 -dose/(T)/2(AUC), for which AUMC is the total area under the first moment of the concentrationtime curve and T is the duration of the infusion. An assumption was made in all calculations that cefoperazone concentrations were at steady state. Renal clearance (CLR) of cefoperazone was calculated as CLR = amount of urine/AUC. The percentage of cefoperazone bound to plasma proteins was calculated by % Bound = (C, -Cf)IC, x 100, for which C, represents the total cefoperazone concentration in plasma and Cf is the free-drug concentration. Values between groups were compared by unpaired t-test analysis.
RESULTS
The mean age standard deviation (SD) of the subjects studied was 27.3 5.0 years. All patients had completed 37 weeks of uncomplicated pregnancy. Indications for abdominal delivery included cephalopelvic disproportion (n = 7), malpresentation (n = 2), and fetal distress (n = 3). None of these subjects had histories of renal or biliary compromise before or during the current pregnancy.
Serum samples were analyzed for cefoperazone content by high-pressure liquid chromatography. A plot of the mean concentrations ( + SDs) of cefoperazone in sera at each time period during the dosage interval is shown in Fig. 1 . The mean peak concentration + SD of cefoperazone in sera after infusion of the 2-g dose was 169.9 + 60. 4 ,ug/ml. The mean trough level at the end of the dosage interval was 6.5 + 5.2 DISCUSSION Cefoperazone is an interesting drug to examine with respect to the parturient because its deposition characteristics differ from that of other cephalosporins. Cefoperazone is eliminated by both renal and nonrenal mechanisms; it has been reported to be excreted mainly in bile, with renal excretion accounting for only 14 to 36% of a dose (3, 6) . Although some alteration in biliary function occurs with pregnancy, this change is small compared with known increases which occur in the glomerular filtration rate of the gravida (8) .
The t1/2 of cefoperazone (152 min) determined from the present study is similar to values (100 to 160 min) reported from other studies of cefoperazone pharmacokinetics in ANTIMICROB. AGENTS CHEMOTHER. humans (3, 6) . In our study population, the mean total clearance + SD of cefoperazone was 1.1 ± 0.4 ml/min per kg, in good agreement with the clearance of 0.98 ml/min per kg, reported by Kimmerich et al. (6) . This consistency with values for nonpregnant women is in distinction from pharmacokinetic studies with cefoxitin and cefotaxime, in which both agents were determined to have high clearances in the sera of postpartum subjects compared with those of nonpregnant controls (1, 2) . The mean renal clearance value + SD calculated from the data obtained in the present investigation was 0.37 ± 0.12 ml/min per kg. This value is slightly higher than the renal clearance for cefoperazone of 0.25 m/min per kg reported by others (5). In our study population, renal clearance accounted for 39o of the clearance of cefoperazone in serum specimens. This represents a greater fraction of the total clearance of the drug being cleared by the kidneys than has been reported in previous studies (11) . The increase in renal clearance of cefoperazone in the postpartum patient is consistent with known physiologic alterations in renal function during pregnancy, as indicated earlier (8) .
The mean state-state volume of distribution ± SD of cefoperazone in our postpartum patient population was 14.2 + 6.0 liters or 0.18 ± 0.04 liters/kg. This value is slightly higher than the Vs5 reported by Standiford et al. (11) of 0.14 + 0.02 liters/kg and may suggest altered distribution of cefoperazone in the postpartum subject. This effect may be due to an increase in extracellular water or to altered protein binding of cefoperazone. While it is recognized that extracellular water volume increases during pregnancy and appears to be responsible for alterations observed in drug distribution (1, 2, 10) , the influence of a decrease in protein binding could play a role in the observation of greater distribution of cefoperazone in the postpartum patient. The altered binding of drugs during pregnancy has been reported for diazepam and salicylate (13) . In both cases, an increase in the drug-free fraction was found in sera from pregnant women. This was found to be related to a decreased albumin concentration in the sera.
It is worthwhile to determine MICs of cefoperazone for various organisms in this particular setting. Specifically, cefoperazone has been approved for use in enterococcal infections, a not uncommon endometrial organism identified in tests of infected postpartum patients. However, at a reported MIC for 90% of strains at 32 to 64 ,ug/ml (9, 12) , this agent quickly falls below these minimum values when administered as a 2-g bolus dose (see Fig. 1 ). Although many infections may be adequately controlled with concentrations in sera not consistently above the MIC for the infecting organism(s), these data suggest that cefoperazone not be used as a first-line drug for enterococcus-associated sepsis.
Although it is difficult to directly compare different studies, due to differences in methodology and study design, our data suggest that drug deposition can be greatly influenced by pregnancy and that these findings may be of importance for determining correct dosages and other therapy for the postpartum patient. Our results demonstrate larger volumes of distribution, lower peak concentrations, and lower plasma protein binding than previously reported (3, 6) . However, unlike other new antimicrobial agents whose excretions are mainly renal, the cefoperazone t1/2 and subsequent trough levels for the parturient more closely resemble those of the nonpregnant subject.
